Skip to content

Therapeutic Effects of Cinnamon-Enriched Cookies on Hypercholesterolemia and Liver Function

Therapeutic Effects of Cinnamon-Enriched Cookies on Hypercholesterolemia and Liver Function

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07740473
Enrollment
40
Registered
2026-07-31
Start date
2024-05-02
Completion date
2024-07-15
Last updated
2026-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidaemia, Liver Biomarkers, Weight Change

Keywords

Cinnamon, Hypercholesterolemia, Liver function, Antioxidants

Brief summary

Cinnamon-enriched cookies were developed and evaluated for their sensory acceptability and potential as a functional food for adults with hyperlipidemia. The findings suggest that incorporating cinnamon into cookies alongside conventional therapy may support cardiovascular and liver health while offering a palatable dietary intervention.

Detailed description

This study developed cinnamon-enriched cookies as a functional food and evaluated their sensory acceptability, physical characteristics, and potential health benefits in adults with hyperlipidemia receiving conventional therapy. The findings highlight the potential of cinnamon-enriched cookies as a convenient, acceptable, and food-based dietary strategy to support cardiovascular and liver health, encouraging the development of functional bakery products for managing hyperlipidemia.

Interventions

DIETARY_SUPPLEMENTTreatment group T1

Conventional therapy + cinnamon-enriched cookie (1 cookie/day)

Sponsors

University of Lahore
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
45 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

Both men and women aged 45-55 participated in the study. The experiment targeted high-cholesterol, triglycerides, and low-density lipoprotein patients (\>220, 150, and 130 mg/dL).

Exclusion criteria

Individuals with diabetes, gastrointestinal issues, documented cinnamon allergies were excluded. \-

Design outcomes

Primary

MeasureTime frameDescription
Anthropometric measurement10 weeksWeight, BMI was measured
Lipid Profile10 weeksLipid Profile was observed

Secondary

MeasureTime frameDescription
Liver Enzymes10 weeksLiver Enzymes were observed

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 1, 2026